Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02575144 | GEM-CLARIDEX: Ld vs BiRd(GEM-CLARIDEX) | unknown | Phase 3 | 286 | PETHEMA FoundationOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT04617821 | AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer | unknown | Phase 3 | 300 | Fudan UniversityOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT05209256 |
| Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC |
| unknown |
| Phase 2 / Phase 3 |
| 90 |
| The First Affiliated Hospital of Henan University of Science and TechnologyOTHER |
| 0 |
| Jan 26, 2022 |
| clinicaltrials |
| NCT05204628 | A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib | unknown | Phase 3 | 238 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 24, 2022 | clinicaltrials |
| NCT00212121 | Radiation Dose Intensity Study in Breast Cancer in Young Women | unknown | Phase 3 | 2,400 | The Netherlands Cancer InstituteOTHER | 2 | Jan 21, 2022 | clinicaltrials |
| NCT02796261 | Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients(STELLAR) | unknown | Phase 3 | 343 | Orbus Therapeutics, Inc.INDUSTRY | 8 | Jan 21, 2022 | clinicaltrials |
| NCT02192671 | HR Versus RFA for HCC in Patients With PHT(HR-HCC/PHT) | unknown | Phase 3 | 120 | Guangxi Medical UniversityOTHER | 1 | Jan 18, 2022 | clinicaltrials |
| NCT03988998 | Radiofrequency Ablation Plus Radiotherapy for Small Hepatocellular Carcinoma | unknown | Phase 3 | 100 | Guangxi Medical UniversityOTHER | 0 | Jan 18, 2022 | clinicaltrials |
| NCT05189067 | Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer | unknown | Phase 2 / Phase 3 | 190 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jan 12, 2022 | clinicaltrials |
| NCT04646564 | Radiotherapy for Extracranial Oligometastatic Breast Cancer | unknown | Phase 3 | 170 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05158608 | Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis(CY25) | unknown | Phase 3 | 100 | National Research Center for Hematology, RussiaNETWORK | 0 | Jan 11, 2022 | clinicaltrials |
| NCT05187481 | Effect of Jianpi Huatan Decoction on Advanced Colorectal Cancer | unknown | Phase 3 | 200 | Xiyuan Hospital of China Academy of Chinese Medical SciencesOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT03801668 | Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma | unknown | Phase 3 | 294 | Huazhong University of Science and TechnologyOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT05175508 | Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS | unknown | Phase 2 / Phase 3 | 180 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT02743923 | Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer | unknown | Phase 3 | 203 | The Netherlands Cancer InstituteOTHER | 1 | Dec 21, 2021 | clinicaltrials |
| NCT05164770 | Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | unknown | Phase 3 | 160 | Shandong Provincial HospitalOTHER_GOV | 1 | Dec 21, 2021 | clinicaltrials |
| NCT05164952 | Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole | unknown | Phase 3 | 50 | Assiut UniversityOTHER | 1 | Dec 21, 2021 | clinicaltrials |
| NCT03668639 | Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin | unknown | Phase 2 / Phase 3 | 80 | Christina RuhlmannOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT05145218 | A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer | unknown | Phase 3 | 405 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 8, 2021 | clinicaltrials |
| NCT04722952 | PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML | unknown | Phase 3 | 30 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT03338647 | SBRT or TACE for Advanced HCC | unknown | Phase 3 | 180 | University of AarhusOTHER | 1 | Dec 2, 2021 | clinicaltrials |
| NCT05136079 | Prophylactic LYMphatic Reconstruction (LYMbR) to Prevent Lymphedema After Node Dissection for Cutaneous Malignancies(LYMbR) | unknown | Phase 3 | 40 | Alberta Health Services, CalgaryOTHER | 1 | Nov 26, 2021 | clinicaltrials |
| NCT04789434 | PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT | unknown | Phase 3 | 94 | Ruijin HospitalOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT05097443 | Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | unknown | Phase 3 | 130 | Shandong Provincial HospitalOTHER_GOV | 1 | Nov 19, 2021 | clinicaltrials |
| NCT04674345 | Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia | unknown | Phase 2 / Phase 3 | 346 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 8, 2021 | clinicaltrials |
| NCT04716114 | A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated(ALIVE) | unknown | Phase 3 | 315 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Nov 2, 2021 | clinicaltrials |
| NCT04287660 | Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients | unknown | Phase 3 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Oct 25, 2021 | clinicaltrials |
| NCT05084872 | Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients(HCQMa) | unknown | Phase 2 / Phase 3 | 30 | University Hospital, ToulouseOTHER | 1 | Oct 20, 2021 | clinicaltrials |
| NCT00942357 | Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer | unknown | Phase 3 | 813 | Gynecologic Oncology GroupNETWORK | 3 | Oct 19, 2021 | clinicaltrials |
| NCT05079438 | Dendrobium Huoshanense Suppository in Rectal Cancer | unknown | Phase 3 | 168 | Zhejiang Cancer HospitalOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT05074966 | The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts | unknown | Phase 3 | 314 | Chinese Academy of Medical SciencesOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT03257241 | A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old(PALG-AML1/2016) | unknown | Phase 3 | 582 | Polish Adult Leukemia GroupOTHER | 2 | Oct 1, 2021 | clinicaltrials |
| NCT00108745 | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer | unknown | Phase 3 | 1,157 | GOG FoundationNETWORK | 1 | Sep 30, 2021 | clinicaltrials |
| NCT00954174 | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer | unknown | Phase 3 | 637 | GOG FoundationNETWORK | 2 | Sep 30, 2021 | clinicaltrials |
| NCT02065687 | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer | unknown | Phase 2 / Phase 3 | 469 | Gynecologic Oncology GroupNETWORK | 1 | Sep 30, 2021 | clinicaltrials |
| NCT03887156 | Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft(Predictor2) | unknown | Phase 2 / Phase 3 | 227 | Assistance Publique - Hôpitaux de ParisOTHER | 3 | Sep 28, 2021 | clinicaltrials |
| NCT04781270 | mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases | unknown | Phase 3 | 308 | Fudan UniversityOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT02242929 | Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma(SCIN) | unknown | Phase 3 | 145 | Maastricht University Medical CenterOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT05056337 | Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC | unknown | Phase 3 | 220 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT05054426 | Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL(NHL-011) | unknown | Phase 3 | 488 | Peking Union Medical College HospitalOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT05049681 | Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell | unknown | Phase 3 | 234 | Feng WangOTHER | 0 | Sep 20, 2021 | clinicaltrials |
| NCT04426955 | Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer | unknown | Phase 3 | 396 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 16, 2021 | clinicaltrials |
| NCT04612439 | Accuracy of VABB Elite 10G Versus BARD 14G CNB | unknown | Phase 3 | 1,470 | Fudan UniversityOTHER | 1 | Sep 14, 2021 | clinicaltrials |
| NCT02934464 | Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers(ARMANI) | unknown | Phase 3 | 280 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT02899169 | Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)(APL16) | unknown | Phase 3 | 110 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT04277403 | HA-WBRT vs SRS in Patients With Multiple Brain Metastases(HipSter) | unknown | Phase 3 | 150 | Medical University InnsbruckOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02512315 | A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma | unknown | Phase 3 | 192 | Sun Yat-sen UniversityOTHER | 1 | Aug 30, 2021 | clinicaltrials |
| NCT04679064 | Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment(NItCHE-MITO33) | unknown | Phase 3 | 427 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT02631239 | MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma | unknown | Phase 3 | 256 | Ruijin HospitalOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT05002686 | Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis | unknown | Phase 2 / Phase 3 | 60 | Ruijin HospitalOTHER | 1 | Aug 24, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Feb 1, 2022source: clinicaltrials